What is the medical use of Ibogaine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Ibogaine should not be used as a treatment for opioid dependence outside of a highly controlled and specialized medical setting due to its significant risks and lack of FDA approval. The use of ibogaine for treating addiction has been studied in various settings, with some studies suggesting potential benefits in reducing withdrawal symptoms and drug cravings 1. However, the treatment carries significant risks, including potentially fatal cardiac arrhythmias, seizures, and interactions with many medications 2, 3, 4.

Key Considerations

  • Ibogaine affects various neurotransmitter systems in the brain, including serotonin, dopamine, and NMDA receptors, which may help reduce withdrawal symptoms and drug cravings.
  • Typical therapeutic doses range from 10-20 mg/kg of body weight, administered in a single session under medical supervision.
  • The treatment is not FDA-approved and is classified as a Schedule I controlled substance in the United States, making it illegal for general use.
  • Medical screening, including ECG, liver function tests, and comprehensive medication review, is essential before administration.

Safety Concerns

  • Potentially fatal cardiac arrhythmias, seizures, and interactions with many medications are significant risks associated with ibogaine use.
  • A systematic review of adverse events associated with ibogaine use found highly heterogeneous results, with acute effects including cardiac, gastrointestinal, neurological, and clinical alterations, and long-lasting effects including persistent cardiac alterations, psychiatric, and neurological signs 2.
  • The lack of large clinical trials and significant safety concerns mean ibogaine should only be considered in specialized settings with proper medical oversight, if at all.

Clinical Use

  • Patients considering ibogaine should be aware that treatment typically involves a 24-36 hour psychedelic experience followed by a recovery period of several days.
  • Ibogaine may provide a useful prototype for discovery and development of innovative pharmacotherapy of addiction, but further research is needed to fully understand its potential benefits and risks 1.
  • Alternative treatments for opioid dependence, such as medication-assisted therapy and behavioral counseling, are available and have a more established safety and efficacy profile.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.